Novacyt S.A. (NVYTF) Stock

About Novacyt S.A.

Novacyt S.A., along with its subsidiaries, specializes in the global development, manufacturing, bespoke design, and commercialization of diagnostic products. These offerings are instrumental in identifying cancer and infectious diseases, reaching markets across the United Kingdom, Europe, the United States, Asia Pacific, the Middle East, and Africa. The company's activities are organized into three primary divisions: Primer Design, Lab21 Products, and IT-IS International. Primer Design is responsible for conceiving, producing, and distributing molecular real-time qPCR testing equipment and reagents specifically for infectious disease diagnosis. Lab21 Products focuses on crafting and delivering a spectrum of protein-based in-vitro diagnostic (IVD) solutions for infectious ailments. Lastly, IT-IS International develops and manufactures PCR devices catering to both the life sciences and food testing industries. Novacyt's customer base includes hospitals and various corporate entities. Founded in 2006, the firm is headquartered in Vélizy-Villacoublay, France.

Novacyt S.A. is headquartered in FR.

Novacyt S.A. (NVYTF) stock trades at $0.48 with a market capitalization of $34.80M. The stock is valued at a price-to-earnings (P/E) ratio of -0.80, price-to-book of 1.10, price-to-sales of 1.05. Over the past 52 weeks the stock has ranged between $0.48 and $0.64, and currently trades 25.0% below its 52-week high.

On profitability, Novacyt S.A. generates a return on equity (ROE) of -96.46%, return on capital employed of -38.25%, an operating margin of -52.36%, a net profit margin of -123.91%.

Official website: www.novacyt.com